

Kawashima A, Tanigawa K, Akama T, Waku H, Sue M, Yoshihara A, Ishido Y, Kobayama K, Takeshita F, Ishii KJ, Hirano H, Kimura H, Sakai T, Ishii N and Suzuki K.	Fragments of genomic DNA released by injured cells activate innate immunity and suppress endocrine function in thyroid.	Endocrinology	152(4)	1702-12	2011
Coban C, Kobiyama K, Aoshi T, Takeshita F, Horii T, Akira S, Ishii KJ.	Novel Strategies to Improve DNA Vaccine Immunogenicity	Curr Gene Ther.	11(6)	479-484	2011
Kimura HJ, Suzuki K, Landek-Salgado MA, Caturegli P, Jouinai N, Kobiyama K, Takeshita F	Application of innate immune molecules for a new class of drugs: infection, inflammation and beyond.	Endocr Metab Immune Disord Drug Target	11(1)	68-75	2011
Matsuzaki-Moriya C, Tu L, Ishida H, Imai T, Suzue K, Hirai M, Tetsutani K, Hamano S, Shimokawa C, Hisaeda H	A critical role for phagocytosis in resistance to malaria in iron-deficient mice	Eur J Immunol.	41(5)	1365-75	2011
Fujimoto K, Karuppuchamy T, Takemura N, Shimohigoshi M, Machida T, Haseda Y, Aoshi T, Ishii KJ, Akira S, Uematsu S	A new subset of CD103 ⁺ CD8 α ⁺ dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity	J Immunol	186(11)	6287-95	2011
Palacpac NM, Arisuen N, Tougan T, Ishii KJ, Horii T	Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate	Vaccine	29(35)	5837-45	2011

Edelson BT, Bradstreet TR, Hildner K, Carrero JA, Frederick KE, Kc W, Belizaire R, <u>Aoshi T</u> , Schreiber RD, Miller MJ, Murphy TL, Unanue ER, Murphy KM	CD8α(+) Dendritic Cells Are an Obligate Cellular Entry Point for Productive Infection by <i>Listeria monocytogenes</i>	Immunity	35(2)	236-48	2011
Aoshi T, Koyama S, Kobiyama K, Akira S, Ishii KJ	Innate and adaptive immune responses to viral infection and vaccination	Current Opinion in Virology	1(4)	226-232	2011
Yildiz Zeyrek F, Palapac N, Yuksel F, Yagi M, Honjo K, Fujita Y, Arisue N, Takeo S, Tanabe K, Horii T, Tsuboi T, <u>Ishii KJ</u> , Coban C	Serologic Markers in Relation to Parasite Exposure History Help to Estimate Transmission Dynamics of <i>Plasmodium vivax</i>	PLoS ONE	6(11)	e28126	2011
Marichal T, <u>Ohata K</u> , Bedoret D, Mesnil C, Sabatel C, <u>Kobiyama K</u> , Lekeux P, Coban C, Akira S, <u>Ishii KJ</u> , Bureau F, Desmet CJ.	DNA released from dying host cells mediates aluminum adjuvant activity.	Nat Med	17(8)	996-1002	2011
Kuroda E, <u>Ishii KJ</u> , Uematsu S, <u>Ohata K</u> , Coban C, Akira S, Aritake K, Urade Y, Morimoto Y.	Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via a NALP3 inflammasome-independent mechanism.	Immunity	34(4)	514-26	2011
Yasuda K, Muto T, Kawagoe T, Matsumoto M, Sasaki Y, Matsushita K, Taki Y, Futatsugi-Yumikura S, Tsutsui H, <u>Ishii KJ</u> , Yoshimoto T, Akira S, Nakanishi K	Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice	Proc Natl Acad Sci U S A.	109(9)	3451-6	2012

Haenuki Y, Matsushita K, Futatsugi-Yumikura S, Ishii KJ , Kawagoe T, Imoto Y, Fujieda S, Yasuda M, Hisa Y, Akira S, Nakanishi K, Yoshimoto T	A critical role of IL-33 in experimental allergic rhinitis	J Allergy Clin Immunol.	130(1)	184-94.e11	2012
Nakayama T, Kashiwagi Y, Kawashima H, Kumagai T, Ishii KJ , Ihara T.	Alum-adjuvanted H5N1 whole virion inactivated vaccine (WIV) enhanced inflammatory cytokine productions.	Vaccine.	6:30(26)	3885-90.	2012
Desmet CJ, Ishii KJ .	Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination.	Nat Rev Immunol.	22:12(7)	479-91	2012
Shoji M, Tachibana M, Katayama K, Tomita K, Tsuzuki S, Sakurai F, Kawabata K, Ishii KJ , Akira S, Mizuguchi H	Type-I IFN signaling is required for the induction of antigen-specific CD8(+) T cell responses by adenovirus vector vaccine in the gut-mucosa	Biochem Biophys Res Commun	17:425(1)	89-93	2012
Tetsutani K, Ishii KJ .	Adjuvants in influenza vaccines.	Vaccine			2012
Nakayama T, Kumagai T, Ishii KJ , Ihara T.	Alum-adjuvanted H5N1 whole virion inactivated vaccine (WIV) induced IgG1 and IgG4 antibody responses in young children.	Vaccine.			2012

Zhao H, Konishi A, Fujita Y, Yagi M, Ohta K, <u>Aoshi T</u> , Itagaki S, Sato S, Narita H, Abdelgelil NH, Inoue M, Culleton R, Kaneko O, Nakagawa A, Horii T, Akira S, <u>Ishii KJ</u> , Coban C	Lipocalin 2 bolsters innate and adaptive immune responses to blood-stage malaria infection by reinforcing host metabolism	Cell Host Microbe	15:12(5)	705-16	2012
Shiraishi K, Hamano M, Ma H, Kawano K, Maitani Y, <u>Aoshi T</u> , <u>Ishii KJ</u> , Yokoyama M.	Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon	J Control Release	10:165(3)	183-90	2012
Jounai N, Kobiyama K, Takeshita F, <u>Ishii KJ</u> .	Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination.	Front Cell Infect Microbiol.	2 (168)	1-13	2012
Kondo T, Kobayashi J, Saitoh T, Maruyama K, <u>Ishii KJ</u> , Barber GN, Komatsu K, Akira S, Kawai T	DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking	Proc Natl Acad Sci U S A	110(8)	2969-74	2013
Tougan T, <u>Aoshi T</u> , Coban C, Katakai Y, Kai C, Yasutomi Y, <u>Ishii KJ</u> , Horii T	TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models	Hum Vaccin Immunother	4:9 (2)	1-8	2013
Kuroda E, Coban C, <u>Ishii KJ</u>	Particulate adjuvant and innate immunity: past achievements, present findings and future prospects.	Int. Rev. Immunol.	In press		2013

<u>Tang CK, Aoshi T, Jounai N, Ito J, Ohata K, Kobiyama, K, Dessailly BH, Kuroda E, Akira S, Mizuguchi K, Coban C and Ishii KJ</u>	The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant	PLOS one	In press		2013
小山正平、貫和敏博、石井 健	インフルエンザウイルスワクチンの考え方と自然免疫	分子呼吸器病	Vol 14(1)	42-45	2010
東岸 任弘、石井 健、堀井 俊宏	マラリアワクチンの臨床開発	Drug Delivery System	Vol. 25No. 1	37-45	2010
青枝大貴	リステリア感染脾臓における宿主-病原体ダイナミクス	医学のあゆみ	232巻13号	1271-1276	2010
小檜山康司、石井 健	アジュバントに関する最新の話	臨床と微生物	37(3)	187-194	2010
小檜山康司、石井 健	自然免疫とワクチン開発	医学のあゆみ	Vol. 234 No. 5	608-614	2010
小檜山康司、石井 健	DNAセンサーとその生理的意義	細胞工学	Vol. 29 No. 10	1004-1013	2010
青枝大貴、石井 健	ワクチンを考えるうえで必要な免疫の知識	臨床検査	Vol. 54 No. 11	1220-1229	2010
小山正平、石井 健	ワクチンアジュバントの必要性和安全性	医学のあゆみ	234(3)	217-221	2010
鉄谷耕平、石井 健	アジュヴァント小史	臨床とウイルス	38(5)	367-378	2010
津久井利広、Coban, Ceveyir, 八木正典、大畑敬一、猪狩義勝、福井真人、堀井俊宏、審良静男、石井 健	マラリアヘモゾインに対するTLR9での反応と免疫増強効果	臨床免疫・アレルギー科	55(1)	28-34	2011
岡田 潔、堀井俊宏、石井 健、鉄谷耕平	トラベラーズマラリアワクチンの臨床試験	臨床評価	Vol. 39, No. 2	281-6	2011

津久井利広、(他8名)石井健	マラリアヘモジンに対するTLR9での反応と免疫増強効果	臨床免疫・アレルギー科	55(1)	28-34	2011
鉄谷耕平、石井健	アジュバント 感染症のワクチン新戦略	Bioclinica	Vol.26 No13	34-39	2011
鉄谷耕平、石井健	新たなアジュバントの臨床応用へむけて	ファーマメディカ	29(4)	9-16	2011
鉄谷耕平、石井健	ワクチンアジュバントの現状と今後	医薬品医療機器レギュラトリーサイエンス	42(8)	650-658	2011
青枝大貴、石井健	ワクチン基礎研究の最新動向と展望；ワクチンアジュバント	日本臨床	69巻9号	1547-53	2011
城内直、小檜山康司、石井健、武下文彦	NLRP4によるautophagyの抑制	臨床免疫・アレルギー科	第57巻第1号	95-103	2012
青枝大貴、石井健	自然免疫と次世代ワクチン開発	Drug Delivery System	Vol. 27, No. 1	19-27	2012
石井 健	宿主の生体バリア -腸管、肺、皮膚における新たな免疫細胞とその機能	実験医学増刊	vol. 30 No. 20	134(3292)-137(3295).	2012
石井 健	感染・共生・生体防御研究から生まれる新たな疾患予防、治療法ターゲット.	実験医学増刊	vol. 30 No. 20	172(3330)-175(3333).	2012
黒田悦史	粒子アジュバントのメカニズム	実験医学増刊	vol. 30 No. 20	203(3361)-208(3366)	2012
城内 直、石井 健	細胞外核酸の生物学的意義と臨床応用	実験医学増刊	vol. 30 No. 20	209(3367)-216(3374)	2012
小檜山康司、石井 健	自然免疫メカニズムを利用するワクチンアジュバント開発	THE LUNG	20(4)	54-61	2012
鉄谷耕平、石井 健	アジュバント開発研究の展開：自然免疫から審査行政.	ファームテクジャパン	28(4)	45-52	2012
鉄谷耕平、石井 健	ワクチンアジュバントの現状と展望	レギュラトリーサイエンス学会誌	2(2)	149-158	2012

石井 健	トップランナーに聞く 核酸による自然免疫および獲得免疫の制御機構の研究と核酸アジュバントのワクチンへの応用研究	最新医学	68(2)	107-111	2013
大西 元康、石井 健	ワクチン (アジュバント) デザインの新展開	医薬ジャーナル	49(2)	699-705	2013
城内 直、石井 健	感染と免疫	Medicina	50(3)	406-411	2013

Immunogenicity of Whole-Parasite Vaccines against *Plasmodium falciparum* Involves Malarial Hemozoin and Host TLR9

Cevayir Coban,¹ Yoshikatsu Igari,^{1,5} Masanori Yagi,² Thornik Reimer,⁴ Shohei Koyama,¹ Taiki Aoshi,² Keiichi Ohata,^{1,5} Toshihiro Tsukui,⁵ Fumihiko Takeshita,⁶ Kazuo Sakurai,⁷ Takahisa Ikegami,³ Atsushi Nakagawa,³ Toshihiro Horii,² Gabriel Nuñez,⁴ Ken J. Ishii,^{1,2,*} and Shizuo Akira^{1,*}

¹Laboratory of Host Defense, WPI Immunology Frontier Research Center

²Department of Molecular Protozoology, Research Institute for Microbial Diseases

³Institute for Protein Research

Osaka University, Osaka 565-0871, Japan

⁴Department of Pathology and Comprehensive Cancer Center, The University of Michigan Medical School, Ann Arbor, MI 48109, USA

⁵ZENOAG, Nippon Zenyaku Kogyo Co. Ltd., Fukushima 963-0196, Japan

⁶Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan

⁷Department of Chemical Processes & Environments, The University of Kitakyushu, Fukuoka 808-0135, Japan

*Correspondence: kenishii@biken.osaka-u.ac.jp (K.J.I.), sakira@biken.osaka-u.ac.jp (S.A.)

DOI 10.1016/j.chom.2009.12.003

SUMMARY

Although whole-parasite vaccine strategies for malaria infection have regained attention, their immunological mechanisms of action remain unclear. We find that immunization of mice with a crude blood stage extract of the malaria parasite *Plasmodium falciparum* elicits parasite antigen-specific immune responses via Toll-like receptor (TLR) 9 and that the malarial heme-detoxification byproduct, hemozoin (HZ), but not malarial DNA, produces a potent adjuvant effect. Malarial and synthetic (s)HZ bound TLR9 directly to induce conformational changes in the receptor. The adjuvant effect of sHZ depended on its method of synthesis and particle size. Although natural HZ acts as a TLR9 ligand, the adjuvant effects of synthetic HZ are independent of TLR9 or the NLRP3-inflammasome but are dependent on MyD88. The adjuvant function of sHZ was further validated in a canine antiallergen vaccine model. Thus, HZ can influence adaptive immune responses to malaria infection and may have therapeutic value in vaccine adjuvant development.

INTRODUCTION

Whole-microbe vaccines have been successful in preventing and/or treating many infectious diseases, by harboring not only protective antigens, but also “built-in” adjuvant components capable of activating the innate immune system (Pulendran and Ahmed, 2006; Ishii et al., 2008; Palm and Medzhitov, 2009). In the case of malaria, there is evidence that host protective immunity against blood stage malaria parasites can be achieved in humans as well as in animal models following whole-parasite vaccinations, although large numbers of para-

sites are required (Good, 2009; Doolan et al., 2009). Among parasite-derived molecules, potentially protective antigens have been investigated intensively for vaccine development (Girard et al., 2007; Coppel, 2009). However, the adjuvant components within blood stage parasites have not been explored; likely adjuvant components include ligands for innate immune receptors, such as Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (Stevenson and Riley, 2004; Coban et al., 2007a).

There are several candidate molecules in *Plasmodium* parasites that could act as adjuvant components (Schofield et al., 2002; Pichyangkul et al., 2004; Krishnegowda et al., 2005; Coban et al., 2005; Parroche et al., 2007; Seixas et al., 2009). TLR2 and TLR9 have been shown to mediate innate immune system activation by GPI, a heat-labile fraction, and hemozoin (HZ) and DNA derived from *Plasmodium falciparum* (*Pf*) (Krishnegowda et al., 2005; Pichyangkul et al., 2004; Coban et al., 2005; Parroche et al., 2007); however, discrepancies among these findings remain unresolved (Coban et al., 2007a). TLR9 has also been proposed to play important roles in the pathogenesis of cerebral malaria by recruiting immune cells into the brain (Coban et al., 2007b; Griffith et al., 2007), or in that of severe malaria owing to the induction of regulatory T cells and/or synergy with interferon γ (IFN γ) signaling (Hisaeda et al., 2008; Franklin et al., 2009), but this is also controversial with some reports suggesting that this is not the case (Lepeniev et al., 2008; Togbe et al., 2007). In addition, recent reports suggest that uric acid is released during malaria infection (Orengo et al., 2008), thereby activating the innate immune system presumably via NLRs, particularly NLRP3 (also known as NALP3) and its adaptor molecule apoptosis-associated speck-like protein containing a CARD domain (ASC), leading to caspase-1 activation (Franchi et al., 2009).

We therefore investigated further whether TLRs, and TLR9 in particular, as well as other innate immune receptors such as NLRs, are involved in *Pf*-mediated innate and adaptive immune responses, and whether HZ plays any role in such adaptive immune responses. We found that *Pf* whole-parasite crude




Figure 1. *Pf* Crude Extract Contains an Adjuvant Element for Coadministered Malaria Antigens in a TLR9-Dependent Manner
 (A–C) Serum anti-*Pf* crude extract-specific IgG (A) and IgG2c antibody responses (B) and IFN γ from cultured spleen cells (C) were measured by ELISA at 3 weeks after the intraperitoneal immunizations with *Pf* crude extract. See also Figure S1.
 (D and E) Serum anti-*Pf* crude extract-IgG antibody responses of *Nlrp3*^{-/-} and *Asc*^{-/-} mice. (E) shows levels only after prime immunization.
 (F) Sera from WT and *Tlr9*^{-/-} mice were analyzed for anti-*Pf* SERA5-specific IgG responses. The results shown are representative of at least two independent experiments with three to five mice per group. (**p* < 0.05; mean levels of serum antibodies \pm standard deviation [SD]).

extracts elicit parasite antigen-specific adaptive immune responses via TLR9, but not via NLRP3 or ASC. The malarial product HZ showed a potent adjuvant effect without any requirement for DNA. Further analysis at the molecular and atomic levels revealed that TLR9 binds to HZ directly and specifically, in a manner that depends on particular motifs and amino acid sequences, similar to its binding of CpG DNA, a well-known TLR9 ligand. A synthetic version of HZ also displayed a strong adjuvant effect; however, its optimal response was quite variable and dependent on its method of synthesis as well as its structural appearance.

RESULTS

A *Pf* Crude Extract Contains a TLR9 Ligand as a Built-in Adjuvant for Coadministered Malaria Antigens

To examine the possible adjuvant effects of whole parasites, we prepared a large quantity of whole-parasite antigens by freeze-thawing of *Pf*-infected red blood cells. The resulting extract, designated the *Pf* crude extract, contained products from both parasites and host red blood cells was immunized into mice. Three weeks after immunization, without any additional adjuvant, a significantly higher titer of serum *Pf* crude extract-specific immunoglobulin G (IgG) was detected compared with the titers in naive mice and mice immunized with a normal red blood cell

extract, in a dose-dependent manner (Figure 1A and data not shown). The antibody titers were 10 times higher after boost immunizations (Figure 1D).

We subsequently examined whether the immunogenicity of the whole-parasite vaccine was altered in the absence of TLR9, because TLR9 has been shown to mediate innate immune system activation by a heat-labile fraction, HZ and DNA derived from *Pf* (Coban et al., 2007a). Accordingly, mice lacking TLR9 showed significantly lower serum IgG (mainly IgG2c) responses and T-cell-specific IFN γ levels than wild-type mice (Figures 1A–1C). This TLR9-dependent adjuvant effect of whole-parasite antigens was specific for the immunizing *Pf* antigens, such as *Pf* SERA5 and *Pf* MSP1 (Figure 1F and data not shown). TLR9-dependent IgG responses were also observed for IgG2b and IgG3, but not for IgG1 (see Figures S1A–S1C available online). These data clearly demonstrate that *Pf* crude extract possesses a TLR9 ligand as a built-in adjuvant for coadministered malaria antigens.

The ASC-Inflammasome Is Not Involved in the Adjuvant Effect of *Pf* Crude Extract

We next investigated whether the inflammasome and its components were involved, given the fact that *Plasmodium* parasites grown in erythrocytes increase the concentration of uric acid, a known NLRP3 ligand that acts as a “danger signal” and




Figure 2. Malarial DNA Has No Role in the Adjuvanticity of *Pf* Crude Extract

(A) Serum anti-*Pf* crude extract-specific IgG antibody responses after immunization with DNase-I-treated and DNase-I-untreated *Pf* crude extracts. (n = 5 mice per group; mean ± SD). See also Figure S2B.

(B) Specific binding of rTLR2 or rTLR9 proteins to the coated *Pf* crude extract measured by ELISA. See also Figure S2A.

(C and D) Specific binding of rTLR9 protein to the coated DNase-I-treated or DNase-I-untreated *Pf* crude extract (C), or to *Pf* DNA or DNase-I-treated *Pf* DNA (D). See also Figure S2B.

activates the ASC-inflammasome (Orengo et al., 2008). Moreover, recent studies suggest that DNA from any living organism may activate the ASC-inflammasome, independently of TLR9 (Muruve et al., 2008; Takeshita and Ishii, 2008), and that this may be mediated by AIM2 (Roberts et al., 2009; Hornung et al., 2009; Fernandes-Alnemri et al., 2009; Burckstummer et al., 2009). However, neither ASC- nor NLRP3-deficient mice showed any reduction in the adjuvant effect of *Pf* crude extract (Figures 1D and 1E). These data suggest that the critical adjuvant activity within *Pf* crude extract is mediated by TLR9, but not ASC-inflammasome.

***Pf* DNA Is Not Involved in the Adjuvant Effect of *Pf* Crude Extract**

What components of the malaria parasite are responsible for the TLR9-dependent adjuvant effect? Although immune recognition of malarial HZ by TLR9 has been previously demonstrated in vitro and in vivo (Coban et al., 2005), another study suggested that HZ itself was immunologically inert, and that TLR9-dependent immune activation is instead caused by HZ-conjugated malarial DNA (Parroche et al., 2007). To investigate whether Plasmodium DNA is responsible for the TLR9-dependent adjuvant effect of *Pf* crude extract, DNA was removed by DNase-I treatment. To confirm that DNA was successfully removed from *Pf* crude extract, we performed *Pf* typing polymerase chain reaction (PCR) based on the nested PCR technique (Snounou et al., 1993), and did not find a trace of *Pf*DNA after DNase-treatment (Figure S2B). After immunizations, we found that the TLR9-dependent adjuvant effect of whole-parasite antigens was not affected by DNase-I treatment (Figure 2A), suggesting that DNA is not the TLR9-dependent adjuvant component of *Pf* crude extract.

A ligand is defined as a molecule with affinity and specificity for binding directly to a receptor. To examine such direct interactions between TLR9 and *Pf* crude extract, we established an enzyme-linked immunosorbent assay (ELISA)-based binding assay. Both rTLR9 and rTLR2 showed specific interactions with their cognate ligands (Figure S2A), confirming previous findings (Rutz et al., 2004). When the *Pf* crude extract was tested for

binding to rTLR9 and rTLR2, we found that TLR9, and to a lesser extent TLR2, interacted strongly and in a dose-dependent manner with the *Pf* crude extract (Figure 2B), consistent with the findings of a previous report (Parroche et al., 2007). However, in sharp contrast with their findings, DNase-I treatment of the *Pf* crude extract did not alter its interaction with rTLR9, while the same DNase-I treatment abrogated TLR9 binding to *Pf* genomic DNA (Figures 2C and 2D). Of note, in contrast to the findings of Parroche et al., several attempts using nuclease treatment of *Pf* crude extract with several nuclease sources, showed either no effect on *Pf* crude extract binding to TLR9 or even nonspecific binding to TLR9 protein (Figures S2B and data not shown). Taken together, these data clearly demonstrate that some component of the *Pf* crude extract acts as a TLR9 ligand, mediates adaptive immune responses through TLR9, and directly binds to rTLR9 in a specific manner, and that this interaction does not require or involve DNA.

Hemozoin Binds Specifically to and Changes the Conformation of TLR9

After eliminating the possible involvement of genomic DNA in *Pf* crude extract adjuvanticity, we next investigated the role of hemozoin as a possible adjuvant molecule in the *Pf* crude extract. Given that it is not possible to deplete hemozoin from *Pf* crude extract without denaturing the malarial antigens (Figure S2C), and that using extensively purified natural *Pf*HZ would always be questioned on the basis of its purity, we used synthetic hemozoin derived from a highly pure source and thought to be identical to natural HZ (Pagola et al., 2000). Competition assays were then performed to investigate whether sHZ could block the binding of TLR9 protein to *Pf* crude extract. TLR9 binding to the coated *Pf* crude extract was measured in the presence of sHZ, CpG DNA (another known TLR9 ligand) or monosodium urate crystals (MSU). MSU crystals are insoluble immunostimulatory crystals that activate the innate immune system in a TLR9-independent manner (Martinon et al., 2006), because they form crystals that resemble sHZ in size and rod shape by surface electron microscopy (Figure S2E). TLR9 binding to the *Pf* crude extract was blocked by sHZ in a dose-dependent manner, as




Figure 3. Synthetic Hemozoin Competes with *Pf* Crude Extract or CpG DNA for Binding to rTLR9 Protein

(A–C) Specific competition between the *Pf* crude extract and sHZ (A), CpG DNA (B) or MSU (C) was measured by ELISA.

(D–F) Conformational changes of rTLR9 protein were measured by CD in the presence and absence of sHZ (D), CpG DNA (E), or MSU (F). See also Figures S2C and S2F. All experiments were repeated at least five times with similar results.

well as CpG DNA (Figures 3A and 3B). On the other hand, MSU did not alter the binding of TLR9 to *Pf* crude extract (Figure 3C). Latz et al. recently demonstrated that TLR9 protein changes its conformation upon ligation (Latz et al., 2007). To monitor the conformational changes in the rTLR9 protein accompanying binding of its ligands, circular dichroism (CD) measurements were performed. Specifically, the CD spectra of rTLR9 protein were measured with or without the ligands at pH 5.5. The CD spectra of rTLR9 were altered by CpG DNA and sHZ, but not

MSU, in a dose-dependent manner, characterized by remarkable spectral changes with shifts of the zero crossing point (Figures 3D–3F and Figure S2C). We also performed similar studies with soluble hemin that showed similar pattern and changed the conformation of rTLR9 as sHZ did, but not synthetic dsRNA (poly I:C) (Figure S2F). Taken together, these results demonstrate that sHZ can compete with *Pf* crude extract for binding to rTLR9 and change its conformation in a similar manner to CpG DNA.




Figure 4. Peptide Regions in the Human TLR9 Sequence that Bind to *Pf* Crude Extract, Hemin, and CpG DNA

(A) Peptide sequences that are specific to human TLR9 extracellular domain and their binding to *Pf* crude extract, hemin and CpG DNA are investigated by ELISA. (B) Binding of the peptides in which CysXXCys and Cys were respectively replaced with SerXXSer and Ser, as investigated by ELISA. Cys residues are labeled red, Ser residues are green. (C and D) Interaction of the peptide VGGNCRRCDH and its mutant to various concentrations of hemin (C) or CpG DNA (D), as investigated by NMR titration. See also Figure S3. One-dimensional ^1H spectra of the peptides were obtained upon the addition of hemin or CpG DNA, and they are shown overlapped.

Direct and Specific Interaction between Hemozoin and TLR9 Observed at the Molecular and Atomic Levels

To further clarify the nature of the interaction between TLR9 and HZ, short peptides containing unique sequences of the TLR9 extracellular domain (sequences that are specific to the TLR9 extracellular domain and not contained in the extracellular domains of the other TLR family proteins) were synthesized and screened to identify the binding site(s) for TLR9 ligands. The peptides were subjected to ELISA-based binding assays with various TLR9 ligands, namely, *Pf* crude extract, hemin (a single unit of HZ) and CpG DNA (Figure 4A). Only four peptides, all of which had unique CysXXCys or Cys motifs similar to zinc finger motifs, bound to these ligands. Cysteine was required for the binding of these peptides as revealed by the same assays using mutant peptides (in which Cys was mutated to Ser) for which the binding ability was completely abrogated (Figure 4B). To analyze the binding sites in the peptides at an atomic level, nuclear magnetic resonance (NMR) titration was

performed with peptides and CpG DNA and hemin. Using the peptide VGGNCRRCDH, which had the highest binding to the TLR9 ligands (Figure 4A), and its mutant peptide, the concentration of hemin and CpG DNA was increased stepwise and the spectral changes caused by hemin and CpG DNA were followed for each, as shown in Figures S3A and S3B and in greater detail in Figures 4C and 4D. Both hemin and CpG DNA shifted a peak at a ^1H resonance frequency of 8.2 ppm and slightly shifted at 7.1 and 7.8 ppm; all peaks were broadened to a lower intensity, upon addition of increasing concentrations of hemin, although no significant broadening was observed for CpG DNA (Figures 4C and 4D). When we performed the same titration experiments using the mutant peptides that lack Cys, we observed no such shifts (Figures 4C and 4D), although a decrease in intensity still remained upon increasing the concentration of hemin. These results indicate that TLR9 binds both HZ and CpG DNA and suggest that 4 cysteine residues may play an important role in the interaction between TLR9 and its ligands.




Figure 5. Adjuvanticity of Synthetic Hemozoin Crystals Depends on Their Size, with Smaller Crystals Showing a Better Adjuvant Effect

(A and B) FESEM images of sHZ synthesized by two different methods as described in Experimental Procedures. Scale bars, 500 nm.

(C) Serum OVA-specific IgG responses of C57B/6 mice s.c. immunized with OVA with or without sHZ purified by method 1 or method 2. See also Figure S4A–S4C.

(D) sHZ crystals produced by method 1 were size-differentiated using a laser-scattering particle size distribution analyzer.

(E) Mice were immunized to analyze the adjuvant effects of different sizes of sHZ (50–200 nm and 2–20 µm) and hemin (<50 nm). See also Figure S7. Results are representative of at least two independent experiments (mean \pm SD; n = 3–5 mice per group).

Hemozoin Acts as a Potent Adjuvant, and Its Adjuvanticity Depends on Its Size

Is pure synthetic HZ a good adjuvant *in vivo*? Given the fact that various hemin chloride sources and methods can be used to synthesize sHZ, we first employed several production protocols to investigate the adjuvant properties of sHZ (Egan, 2008) using ultrapure hemin chloride. We found that two commonly used methods for synthesizing sHZ from hemin chloride produced crystals with a distinct appearance that differed in their adjuvant effects. With one method, HZ polymerized in the presence of acetic acid (method 1) and produced crystals that ranged in diameter from 50 nm to 1 µm, while the other method, involving an organic base (method 2), produced crystals that ranged in size from 1 to 5 µm as visualized by field emission scanning electron microscopy (FESEM) (Figures 5A and 5B). When mice were immunized with the model protein antigens ovalbumin (OVA) (or in some cases human serum albumin [HSA]) in the presence or absence of sHZ produced by method 1 or 2, the OVA-specific total IgG responses were significantly higher with sHZ produced by method 1 than with sHZ produced by method 2 (Figure 5C). Interestingly, when we separated the HZ produced by method 1 into two size distributions using a laser-scattering particle size distribution analyzer (Figure 5D), larger sHZ particles (up to 20 µm in size) were counted. It should be noted that sHZ crystals tend to make aggregates that the larger HZ particles might be attributed to the aggregation. Nevertheless, sHZ with sizes between 50 and 200 nm had optimal adjuvant effects compared with larger sHZ molecules (2–20 µm) and the smaller hemin monomer (<50 nm) (Figure 5E). We also examined different administration routes to investigate the adjuvant effects of sHZ

such as subcutaneous (s.c.) and intranasal (i.n.) routes, and found that antigen-specific antibody responses were induced in a dose-dependent manner (Figures S4A and S4B and Figure 6A). There were no detectable OVA-specific IFN γ or interleukin (IL)-17 production by spleen cells, but substantial amounts of OVA-specific IL-13 and IL-5 were detected (Figure S4C). Analysis of the IgG isotypes elevated by sHZ coadministration showed that mainly IgG1 isotypes were elevated, followed by IgG2b and IgG2c, in mice (Figure 6B); this response was very potent when compared with those elicited by the adjuvants alum or CpG DNA (Figure 6C). On the other hand, sHZ administration elevated mainly IgG1 responses, while CpG DNA elevated mainly IgG2a (Figure S4D). Therefore, sHZ is indeed a potent adjuvant for protein vaccines, with optimal sizes of 20–200 nm, which coincide with the sizes of other particle adjuvants taken up by antigen-presenting cells via receptor-mediated endocytosis (McGee et al., 1997; Xiang et al., 2006).

Synthetic Hemozoin's Adjuvant Effect Is Mediated by MyD88, but Not TLR9 or the Inflammasome/IL-1 β

We further investigated how the HZ adjuvant effect was regulated. To examine whether the potent adjuvant effect of sHZ was mediated by TLR9 and through MyD88, mice lacking TLR9 and MyD88 were immunized with OVA plus sHZ. MyD88-deficient mice failed to elicit a serum anti-OVA antibody titer (Figure 6D). By contrast, however, TLR9-deficient mice showed comparable anti-OVA titers to those in wild-type mice, suggesting that there are distinct mechanisms for the adjuvant effects of sHZ other than TLR9, any of which seem to culminate in




Figure 6. Synthetic Hemozoin's Potent Adjuvant Effect Is Mediated by MyD88 but Independently of TLR9 and the Inflammasome
(A and B) Mice were immunized with HSA and various concentrations of sHZ. Serum HSA-specific IgG (A) and IgG isotypes (B) were measured by ELISA (mean \pm SD).
(C) Comparison of the adjuvant effects of alum, CpG DNA, and sHZ. Balb/c mice were immunized s.c. with OVA and alum (200 μ g), CpG DNA (50 μ g), and sHZ (800 μ g), and serum OVA-specific IgG responses were determined after boost immunizations by ELISA (mean \pm standard error; n = 3). *p < 0.05 compared with OVA-alone group. See also Figure S4D.
(D–F) Serum OVA-specific IgG responses of *Myd88*^{-/-} and *Tlr9*^{-/-} mice (D), *Nlrp3*^{-/-} and *Asc*^{-/-} mice (E), and *IL1R*^{-/-} mice (F) after boost immunizations were determined by ELISA (**p < 0.01; mean \pm SD). Wild-type (n = 5–6); *Myd88*^{-/-} (n = 6); *TLR9*^{-/-} (n = 6); *Nlrp3*^{-/-} (n = 3); *Asc*^{-/-} (n = 6) and *IL1R*^{-/-} (n = 5). See also Figures S5A–S5C and Figure S6. Experiments are representative of at least two independent experiments.

MyD88-dependent signals. We confirmed these findings by obtaining similar results with HSA (Figures S5A and S5B).

Particles like MSU crystals have recently been shown to be recognized by NOD-like receptors (NLRP3 in the case of MSU) and form large cytosolic complexes, collectively called the inflammasome. We were interested in clarifying whether the adjuvanticity of sHZ, whose appearance resembles MSU crystals (Figure 5A and Figure S2D), could involve the inflammasome. In the same set of OVA or HSA immunization protocols, mice deficient in ASC or NLRP3 elicited normal antibody responses (Figure 6E and Figure S5B) as well as IL1R-deficient mice (Figure 6F and Figure S5C). These results suggest that inflammasome/IL-1 β pathway have a minimal role in the adjuvant effect of sHZ.

To examine whether sHZ-induced inflammation occurs in vivo, we measured neutrophil recruitment. When sHZ was injected intraperitoneally, significant numbers of neutrophils were recruited into the peritoneum within 24 hr (Figure S6A), and the neutrophil recruitment occurred normally in mice lacking either ASC or TLR9 (Figure S6B). However, mice lacking MyD88 failed to exhibit neutrophil recruitment in response to sHZ injection (Figure S6A).

Synthetic Hemozoin Is a Potent Adjuvant for Malarial Antigens as Well as for an Allergen

It has been previously shown that subclinical infection of healthy human volunteers with red cells infected with *Pf* or immunization of mice with a small number of dead parasites in the presence of CpG DNA or alum can induce cellular immunity and protection (Pombo et al., 2002; Good, 2009). To examine whether sHZ would have a potent adjuvant effect on immunization with *Pf* crude extract from a few parasites, we immunized mice s.c. with 10 μ g total *Pf* crude extract together with sHZ, boosted twice, and measured anti-*Pf* crude extract specific antibody responses. sHZ significantly improved IgG levels (mainly IgG2c and IgG1) against *Pf* crude extract (Figure 7A and data not shown).

To examine whether sHZ could be used in animal species other than mice, we immunized Beagle dogs with house dust mite allergen (Derf2) together with alum and sHZ, and boosted that elevated IgG2 type (but not IgG1) antibodies, which may resemble Th1-like immune responses in dogs (Figure 7B and 7C) (Hou et al., 2006). Accordingly, Derf2-specific IgE responses after Ag challenges were significantly reduced in sHZ coadministered dogs (Figure 7C). It is of note, however, that antibody

responses elicited in mice were dominant with IgG1 isotype, which was different from those in dogs (Figure S5D). These data further suggest that sHZ may serve as a potent Th1-like adjuvant, at least in the canine model, while it acts like a Th2-dominant adjuvant in a murine model.

DISCUSSION

Malaria is still one of the leading pathogens, affecting 40% of the world's population and killing over one million people each year, but a successful vaccine against it not yet available. Owing to the failure of many clinical trials for recombinant vaccines, and recent progress in our understanding of innate immune adjuvant effect of microbial products (Kaisho and Akira, 2002), the whole-parasite vaccine strategy has been regaining attention (Good, 2009; Doolan et al., 2009). Successful vaccination with erythrocytic parasites was achieved using powerful adjuvants, such as CpG DNA (Su et al., 2003). We further demonstrated that an increased dose of a crude extract of *Pf* parasites without adjuvant successfully displayed strong immunogenicity, owing to the enhanced "built-in adjuvant" activity of the parasite. Surprisingly, this adjuvant effect was heavily dependent on TLR9. Because this has been a matter of controversy, the TLR9 ligand in malaria parasite was carefully analyzed again, and we found that DNA is not required for this TLR9-mediated adjuvant effect of the *Pf* crude extract (Figure 2). It is thus reasonable to interpret that the built-in adjuvant in *Pf* crude extract is a non-DNA TLR9 ligand, such as HZ and/or some other heat-labile components as previously reported (Coban et al., 2005; Pichyangkul et al., 2004).

HZ is a heme crystalline dimer generated by parasite digestion of hemoglobin as a byproduct of the heme detoxification system in malaria infection (Arese and Schwarzer, 1997; Hanscheid et al., 2007). It has been proposed to play important roles in pathophysiology during malaria infection, because it activates macrophages and dendritic cells to produce both proinflammatory and anti-inflammatory cytokines and chemokines (Engwerda and Good, 2005; Keller et al., 2006; Hanscheid et al., 2007; Coban et al., 2007a). Although immune recognition of malarial HZ by TLR9 has been demonstrated *in vitro* and *in vivo* (Coban et al., 2005), another study suggested that HZ itself was immunologically inert, and that TLR9-dependent immune activation is instead caused by HZ-conjugated malarial DNA (Parroche et al., 2007).

Parroche et al. suggested that DNase-I treatment of *Pf* crude extract did not remove *Plasmodium* DNA from *Pf*HZ shown by *Pf*-specific PCR (Parroche et al., 2007). When we performed PCR by using the same *Pf*-specific primers, 205 bp PCR product of *Pf* DNA was completely lost after DNase-I treatment (Figure S2B). We further confirmed the absence of *Pf* DNA after treatment of *Pf* crude extract by PCR using the other primers (101 bp product) (data not shown). *In vivo*, this DNase-free *Pf* crude extract displayed potent adjuvant activity via TLR9 (Figure 2A), strongly suggesting that the built-in adjuvant of *Pf* crude extract is not DNA.

What in *Pf* crude extract would be a TLR9 ligand rather than *Pf* DNA? We went on to reconfirm our previous finding that HZ is a TLR9 ligand by examining the definition of a ligand for a receptor, in which a ligand is to directly bind to a receptor in

a specific manner. TLR9 binds directly both HZ and heme, and change its conformation following binding to HZ (Figure 3). Moreover, competition for TLR9 binding occurs among *Pf* crude extract, CpG DNA, and sHZ, further supporting the possibility that HZ fulfills the definition of TLR9 ligand specificity. We also identified the binding motifs in the extracellular domain of TLR9, where cysteine residues play a crucial role in controlling the binding to ligands including *Pf* crude extract, heme, and CpG DNA (Figure 4). Taken together, these findings suggest that the adjuvant component of erythrocytic stage *Pf* parasites contains a TLR9 ligand, most likely HZ, but not DNA.

Involvement of the inflammasome pathways in inflammation during malaria infection, as has been implicated by a recent report (Orengo et al., 2008), was not apparent in the built-in adjuvant effect of whole-parasite vaccination with erythrocytic stage *Pf* crude extract (Figure 1). Consistently, the effect of synthetic HZ was also independent of the NLRP3-ASC inflammasome, as well as IL-1 receptor. It is of note that, while natural HZ in the *Pf* crude extract acts mostly as a TLR9 ligand, sHZ has an adjuvant effect independent of TLR9, but still utilizes the MyD88-dependent pathway. One possible explanation for this difference is that the uptake or ability to break the integrity of phagosomal and/or endosomal membrane of natural and synthetic HZ might differ given that the natural HZ is often covered by *Pf*-derived lipid, protein, or nucleic acids, compared with sHZ as a naked sharp crystal. Another explanation is that, although natural HZ purified from *Pf* cultures is known to be identical to sHZ (Pagola et al., 2000), several purification protocols give different crystal sizes ranging from 50 nm to 20 μ m, which displayed quite different adjuvant activities (Figure 5). The studies are under investigation to examine whether different sizes of sHZ make distinct delivery and interaction with the innate immune cells and their immune receptors.

In addition, recent reports have suggested that immune recognition of and inflammatory response by sHZ is mediated by NLRP3 (Dostert et al., 2009; Griffith et al., 2009; Jaramillo et al., 2009). Although all of these three reports showed that IL-1 β production by macrophages as well as neutrophil recruitment in response to sHZ was reduced in mice lacking NLRP3, precise mechanism of NLRP3-inflammasome activation are yet unclear. Griffith et al. suggested that uric acid is induced by sHZ and that the uric acid is the NLRP3 ligand (Griffith et al., 2009), but Dostert et al. suggested that uric acid is not involved in NLRP3 activation by sHZ (Dostert et al., 2009). Moreover, Jaramillo et al. showed elegantly that sHZ activates Lyn/Syk-mediated intracellular signaling pathway at the upstream of NLRP3 or ASC, indicating the existence of other HZ receptor(s) such as Dectin1, TREM family members, Siglec, or DAP12 (Jaramillo et al., 2009). Although the involvement of NLRP3 in sHZ-induced IL-1 β or the following inflammatory response may play an important role in pathogenesis of malaria infections, we clearly demonstrate that NLRP3 as well as ASC, IL-1 receptor is not involved in sHZ-adjuvant activity (Figure 6), suggesting that there may be additional receptor(s) as well as pathway(s) for HZ-induced innate and adaptive immune activations.

Finally we found that sHZ acts as a potent adjuvant only when its synthesis method and size were optimized (Figure 5). This adjuvant effect of HZ for protein vaccines was observed with different model antigens, such as OVA and HSA, and via different




Figure 7. Synthetic Hemozoin Could Be Used as Adjuvant for Whole-Blood Malaria Antigens and Against Canine Allergy
(A) WT mice were immunized s.c. with 10 μ g Pf crude extract and sHZ and were boosted twice. Serum Pf crude extract-specific IgG responses were analyzed by ELISA (mean \pm SD; n = 4 per group).
(B and C) ELISA serum anti-Derf2-specific IgG2, IgG1 (B), and IgE (C) responses of Beagle dogs immunized with Derf2 antigen formulated with or without alum and alum + sHZ. See also Figure S5D. Experiments were repeated twice using four animals per group (**p < 0.01).

immunization routes, such as s.c. and i.n. immunization. It is of note that unlike CpG DNA, which has species-specific activity, HZ displayed its adjuvant effect in several animal models for vaccines, including murine, canine and non-human primate models (Figures 5–7, data not shown). In mice, a predominantly IgG1-dominant antibody adjuvant effect observed after HZ-adjuvanted immunization and T cell specific immune responses were mainly IL-13 and IL-5, but not IFN γ or IL-17, suggesting that HZ elicits Th2-type immune responses in mice (Figures 5, 6, and S4). However, by contrast, dog immunization with HZ elicited IgG2-dominant antibody responses, which is considered a Th1-type immune response (Reed and Scott, 1993). sHZ administration in the dog-allergy model was nonetheless very potent to reduce allergen-specific IgE responses (Figure 7), suggesting successful usage of sHZ as an adjuvant in dogs against allergy. Similarly, our data suggested that sHZ could be introduced externally as an adjuvant to improve immunogenicity of whole-malaria vaccines (Figure 7A). Our preliminary data also suggest that, in non-human primates, sHZ could elevate malarial antigen-specific B and T cell responses, and could be used as a vaccine adjuvant for whole-blood stage vaccines (K.J.I., unpublished data). Overall, our results clearly show that HZ possesses inflammatory and adjuvant activities through differential regulation by TLR9 pathways, thereby potentiating its ability to act as a therapeutic target for treating malaria infection, and its usefulness in vaccine adjuvant development.

EXPERIMENTAL PROCEDURES

Reagents

Hemin chloride was from Fluka (HPLC purified, >98% pure), whereas OVA and HSA (low endotoxin) were from Sigma. A synthetic CpG DNA (D35) was from Gene Design Incorporation. DNase-I was from Invitrogen. Zymosan was from Invivogen. MSU crystals were prepared as described elsewhere (Martinson et al., 2006).

Mice and Immunizations

Mice deficient for *MyD88*, *TLR9*, *Asc* or *Nlrp3*, and *Asc* on a C57BL/6 background were generated and used for experiments as described previously (Coban et al., 2005; Franchi and Nunez, 2008). All animal experiments were

performed according to the institutional guidelines approved by the Research Institute for Microbial Diseases and Immunology Frontier Research Center of Osaka University and the University of Michigan.

Wild-type and *Tlr9*^{-/-} mice were immunized intraperitoneally with the Pf crude extract (100 μ l, approximately $\sim 1 \times 10^6$ parasites). Alternatively, mice were immunized with a DNase-I-treated Pf crude extract. At 3 weeks after immunization, antibodies against Pf crude extract antigens in the sera of mice were detected by ELISA.

Various immunization schedules were conducted using either OVA or HSA as antigens. For s.c. immunizations, mice were injected on day 0 with 50 μ g OVA (or 10 μ g HSA) in a total of 200 μ l sHZ solution at various concentrations and boosted on day 10 with 25 μ g OVA (or 10 μ g HSA) in the same sHZ solution. Blood samples were collected from the mice on day 17 for analysis of OVA- or HSA-specific antibody responses. For i.n. immunizations, mice were anesthetized and administered i.n. with 5 μ g OVA with or without 80 μ g sHZ (15 μ l/nose), twice, at 2-week intervals. The mice were sacrificed 10 days after the boost, and serum, bronchoalveolar lavage fluid, and nasal fluid secretion samples were collected for antibody measurements.

Dogs and Allergy Model

Five-month-old Beagle dogs from the breeding colony at Zenoaq Animal Experiment Center (Nippon Zenyaku Kogyo Co., Ltd., Fukushima, Japan) were used. All immunization and sensitization protocols were performed in accordance with the institutional guidelines of and approved by Zenoaq Animal Center Laboratories Committee. Dogs were immunized s.c. on day 0 with 100 μ g Derf2 protein produced in silkworms by a recombinant Baculovirus system, formulated in 500 μ g aluminum hydroxide in a 200 μ g sHZ solution, and boosted on day 14 with the same dose. Four weeks after the boost immunization, dogs were challenged with Derf2 s.c. four times biweekly. Blood samples were collected on days 7, 14, 21, and 28 for analysis of Derf2-specific IgG1 and IgG2 antibody responses, and on day 90 for the measurement of antigen-specific IgE responses.

Preparation of Pf Crude Extract, Natural HZ, Synthetic HZ, and Pf DNA

Mycoplasma-free Pf parasites (3D7) were maintained in culture medium as described previously (Aoki et al., 2002). After synchronization, mature and HZ-rich mostly trophozoite and schizont stage parasites (~4%–5%) were purified by 63% Percoll density centrifugation, washed and resuspended in incomplete medium, freeze-thawed three or four times, and stored at -80° C until use. Each milliliter of HZ-rich Pf crude extract preparation contained approximately 1×10^9 infected erythrocytes. As controls, uninfected human erythrocytes were treated similarly. Pure natural HZ was extensively purified from Pf-infected erythrocytes as described previously (Coban et al., 2005).



sHZ was purified from hemin chloride using two alternative methods (Egan, 2008). Method 1 (acid-catalyzed method) is known to produce smaller and homogenous crystals and was performed as previously described (Coban et al., 2005; Jaramillo et al., 2005). Briefly, 45 mg hemin chloride was dissolved in 4.5 ml 1 N NaOH and neutralized with 1 N HCl. Then, acetic acid was added until the pH reached 4.8, at a constant temperature of 60°C with magnetic stirring. The mixture was allowed to precipitate at room temperature overnight. The precipitate was subjected to washes with 2% SDS-buffered with 0.1 M sodium bicarbonate (pH 9.1) and subsequent extensive washes with 2% SDS, and then six to eight washes with distilled water. Method 2 (anhydrous method in methanol) is known to produce much bigger crystals and was performed as previously described (Bohle et al., 2002). Briefly, hemin chloride (52.2 mg) was dissolved completely in 2 ml 2,6-lutidine L, diluted with 10 ml dimethyl sulfoxide:methanol (1:1 mixture), tightly wrapped with parafilm and left at room temperature for 2 weeks in the dark, before being centrifuged and washed with 10 ml 0.1 M NaHCO₃ for 3 hr. The final product was washed three times with water and methanol, and dried. A stock solution in distilled water was prepared for use in *in vivo* studies and stored at 4°C. The HZ concentration was calculated as either mM or mg/ml after weighing the dried amount of sHZ. Experiments were mostly performed with sHZ prepared by method 1, except for the results shown in Figure 5B. All solutions were prepared and resuspended in endotoxin-free water (double-processed tissue culture water, Sigma-W3500) and stored in the dark at 4°C. There was no detectable level of endotoxin by LAL assay in any HZ preparation. None of the sHZ purified had any other contaminants, such as hemin, as determined by TLC (Figure S7A) or protein/DNA determined by SDS-PAGE at pH 11 and agarose gel, respectively (data not shown). FT-IR and powder X-ray diffraction pattern of the sHZ confirmed that the sample showed the same unit cell parameters as reported previously (Pagola et al., 2000) (Figures S7B and S7C). *Pf* genomic DNA was isolated as reported previously (Kongkasuriyachai et al., 2004).

Recombinant TLR Proteins and Peptides

Recombinant fusion proteins consisting of the extracellular domains of the human TLRs TLR9 (amino acids 1–818) and TLR2 (amino acids 1–588) fused to mouse IgG2b-Fc were constructed by amplifying the corresponding extracellular domain and ligating the fragment in frame into a pCIneo vector containing the coding sequence for mouse IgG2b-Fc. Fusion proteins were stably expressed in 293-F cells and purified from cell lysates by protein G affinity chromatography. Peptides were derived from unique regions of human *Tlr9* ectodomain sequence and synthesized by Operon Technologies.

Intraperitoneal Neutrophil Recruitment

sHZ (1000 µg) was resuspended in 200 µl PBS and intraperitoneally administered to various mice. At 16–18 hr after injection, the peritoneum was washed with a 30 ml cold PBS containing EDTA (3 mM) and heparin (10 U/ml) and the cells were counted. Neutrophils were identified using PE-conjugated anti-Gr-1 and APC-conjugated anti-CD11b antibodies (Becton Dickinson) in the presence of an anti-CD16 antibody. The stained cells were washed and analyzed using a FACSCalibur system.

Antibody and Cytokine ELISA

The plates were coated with OVA (1 µg/ml) or HSA (10 µg/ml), Derf2 (1 µg/ml) or *Pf* SE36 antigen (3 µg/ml) and analyzed by ELISA using a previously described procedure (Coban et al., 2005; Okech et al., 2006).

Spleens were extracted 3 weeks after the prime immunization and then stimulated with *Pf* crude extract. Seventy-two hours later, the cell culture supernatants were collected and analyzed for IFN γ , IL-13, IL-5, and IL-17 by ELISA (DuoSet ELISA Kit, R&D Systems).

Binding Assay and ELISA

Zymosan (5 µg/ml), CpG DNA (D35; 10 µg/ml), *Pf* crude extract (10 µg/ml), and *Pf* DNA (2 µg/ml) were coated on 96-well plates in PBS overnight at 4°C and then blocked with PBS containing 1% bovine serum albumin. The binding of TLR9 or TLR2 fusion proteins was detected with HRP-labeled mouse anti-IgG (Southern Biotech.). For competition ELISAs, rTLR9 protein was incubated with sHZ, MSU or CpG DNA for 1 hr and then incubated on *Pf* crude extract-coated plates for an additional 1 hr.

CD Spectroscopy

CD spectra were recorded with a J-820 spectropolarimeter (Jasco) using a 1 mm cell at 20°C. Each sample containing 1 µM TLR9 protein with or without a ligand (1 or 10 µM CpG DNA; 10 or 100 µM sHZ, or 10 or 100 µM MSU), was prepared in 20 mM sodium acetate buffer containing 150 mM NaCl at pH 5.5. Twenty spectra were acquired for each sample with a 1 nm bandwidth, a scanning speed of 50 nm per min, and a response time of 2 s, and then averaged. The resultant spectra were calculated after the spectra of rTLR9 were subtracted.

NMR Spectroscopy

¹H-1D NMR measurements were carried out using an AV400M NMR machine (Bruker BioSpin, Rheinstetten, Germany) with a 5 mm Shigemi tube (Shigemi, Tokyo, Japan) at 25°C. Each sample was prepared at a peptide concentration of 250 µM in 20 mM sodium phosphate buffer (pH 7.0) containing 10% (v/v) D₂O for the signal lock. For the measurements with hemin, various concentrations of hemin were prepared and the pH was set to 7.0 to prevent precipitation of hemin. For the measurements with CpG DNA (D35), because the signals from CpG DNA were larger than those from the peptides, the spectrum of D35 was subtracted from the spectra of the peptide-CpG DNA mixture to more easily judge the difference. All NMR data were processed and analyzed using NMRPipe (Delaglio et al., 1995) and Igor Pro (WaveMetrics, Lake Oswego, OR).

FESEM and Particle Size Analysis

Slides were coated with different dilutions of sHZ and images were captured using ultra-high-resolution FESEM (S-4800; Hitachi). The particle size and distribution in the sHZ solution were analyzed using a laser-scattering particle size distribution analyzer (LA-950; Horiba).

Statistical Analysis

Statistical differences between groups were analyzed using the Student's *t* test.

SUPPLEMENTAL INFORMATION

Supplemental Information includes seven figures and can be found with this article online at doi:10.1016/j.chom.2009.12.003.

ACKNOWLEDGMENTS

The authors sincerely thank Drs. N. Palacpac, T. Kanneganti, R. Jerala, M. Treeby, H. Kumar, and Y. Kumagai as well as the other members of Akira Lab and Horii Lab for their comments and for providing reagents, and Drs. S. Takahashi, T. Inoue, T. Inui, Y. Hara, Y. Fujita, K. Murase, M. Nakamura, and S. Itagaki for technical support. We thank Drs. T Tsuboi and K. Tanabe for their kind support and for providing critical reagents, such as *Pf* MSP1. This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology in Japan; from the RT Fund for Technology Development and CREST, JST, Japan; and from the National Institutes of Health. T.R. was supported by a fellowship from the Swiss National Science Foundation. C.C, T.T, K.J.I., and S.A. filed a patent application related to the method and usage of hemozoin as an adjuvant. Y.I., K.O., and T.T. are employees for Nihon ZENOAG, which develops GMP lot of hemozoin, and were funded by JST.

Received: July 29, 2009

Revised: October 20, 2009

Accepted: December 7, 2009

Published: January 20, 2010

REFERENCES

Aoki, S., Li, J., Itagaki, S., Okech, B.A., Egwang, T.G., Matsuoka, H., Palacpac, N.M., Mitamura, T., and Horii, T. (2002). Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth. *J. Biol. Chem.* 277, 47533–47540.

- Arese, P., and Schwarzzer, E. (1997). Malarial pigment (haemozoin): a very active 'inert' substance. *Ann. Trop. Med. Parasitol.* **91**, 501–516.
- Bohle, D.S., Kosar, A.D., and Stephens, P.W. (2002). Phase homogeneity and crystal morphology of the malaria pigment beta-hematin. *Acta Crystallogr. D Biol. Crystallogr.* **58**, 1752–1756.
- Burckstummer, T., Baumann, C., Bluml, S., Dixit, E., Durnberger, G., Jahn, H., Planyavsky, M., Bilban, M., Colinge, J., Bennett, K.L., and Superti-Furga, G. (2009). An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. *Nat. Immunol.* **10**, 266–272.
- Coban, C., Ishii, K.J., Horii, T., and Akira, S. (2007a). Manipulation of host innate immune responses by the malaria parasite. *Trends Microbiol.* **15**, 271–278.
- Coban, C., Ishii, K.J., Kawai, T., Hemmi, H., Sato, S., Uematsu, S., Yamamoto, M., Takeuchi, O., Itagaki, S., Kumar, N., et al. (2005). Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. *J. Exp. Med.* **201**, 19–25.
- Coban, C., Ishii, K.J., Uematsu, S., Arisue, N., Sato, S., Yamamoto, M., Kawai, T., Takeuchi, O., Hisaeda, H., Horii, T., and Akira, S. (2007b). Pathological role of Toll-like receptor signaling in cerebral malaria. *Int. Immunol.* **19**, 67–79.
- Coppel, R.L. (2009). Vaccinating with the genome: a Sisyphean task? *Trends Parasitol.* **25**, 67–79.
- Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J., and Bax, A. (1995). NMRPipe: a multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR* **6**, 277–293.
- Doolan, D.L., Dobano, C., and Baird, J.K. (2009). Acquired immunity to malaria. *Clin. Microbiol. Rev.* **22**, 13–36.
- Dostert, C., Guarda, G., Romero, J.F., Menu, P., Gross, O., Tardivel, A., Suva, M.L., Stehle, J.C., Kopf, M., Stamenkovic, I., et al. (2009). Malarial hemozoin is a Nalp3 inflammasome activating danger signal. *PLoS ONE* **4**, e6510.
- Egan, T.J. (2008). Recent advances in understanding the mechanism of hemozoin (malaria pigment) formation. *J. Inorg. Biochem.* **102**, 1288–1299.
- Engwerda, C.R., and Good, M.F. (2005). Interactions between malaria parasites and the host immune system. *Curr. Opin. Immunol.* **17**, 381–387.
- Fernandes-Alnemri, T., Yu, J.W., Datta, P., Wu, J., and Alnemri, E.S. (2009). AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. *Nature* **458**, 509–513.
- Franchi, L., Eigenbrod, T., Munoz-Planillo, R., and Nunez, G. (2009). The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. *Nat. Immunol.* **10**, 241–247.
- Franchi, L., and Nunez, G. (2008). The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1 β production but dispensable for adjuvant activity. *Eur. J. Immunol.* **38**, 2085–2089.
- Franklin, B.S., Parroche, P., Ataide, M.A., Lauw, F., Ropert, C., de Oliveira, R.B., Pereira, D., Tada, M.S., Nogueira, P., da Silva, L.H., et al. (2009). Malaria primes the innate immune response due to interferon-gamma induced enhancement of toll-like receptor expression and function. *Proc. Natl. Acad. Sci. USA* **106**, 5789–5794.
- Girard, M.P., Reed, Z.H., Friede, M., and Kieny, M.P. (2007). A review of human vaccine research and development: malaria. *Vaccine* **25**, 1567–1580.
- Good, M.F. (2009). The hope but challenge for developing a vaccine that might control malaria. *Eur. J. Immunol.* **39**, 939–943.
- Griffith, J.W., O'Connor, C., Bernard, K., Town, T., Goldstein, D.R., and Bucala, R. (2007). Toll-like receptor modulation of murine cerebral malaria is dependent on the genetic background of the host. *J. Infect. Dis.* **196**, 1553–1564.
- Griffith, J.W., Sun, T., McIntosh, M.T., and Bucala, R. (2009). Pure Hemozoin is inflammatory in vivo and activates the NALP3 inflammasome via release of uric acid. *J. Immunol.* **183**, 5208–5220.
- Hanscheld, T., Egan, T.J., and Grobusch, M.P. (2007). Haemozoin: from melatonin pigment to drug target, diagnostic tool, and immune modulator. *Lancet Infect. Dis.* **7**, 675–685.
- Hisaeda, H., Tetsutani, K., Imai, T., Moriya, C., Tu, L., Hamano, S., Duan, X., Chou, B., Ishida, H., Aramaki, A., et al. (2008). Malaria parasites require TLR9 signaling for immune evasion by activating regulatory T cells. *J. Immunol.* **180**, 2496–2503.
- Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D.R., Latz, E., and Fitzgerald, K.A. (2009). AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. *Nature* **458**, 514–518.
- Hou, C.C., Day, M.J., Nuttall, T.J., and Hill, P.B. (2006). Evaluation of IgG subclass responses against *Dermatophagoides farinae* allergens in healthy and atopic dogs. *Vet. Dermatol.* **17**, 103–110.
- Ishii, K.J., Koyama, S., Nakagawa, A., Coban, C., and Akira, S. (2008). Host innate immune receptors and beyond: making sense of microbial infections. *Cell Host Microbe* **3**, 352–363.
- Jaramillo, M., Bellemare, M.J., Martel, C., Shio, M.T., Contreras, A.P., Godbout, M., Roger, M., Gaudreault, E., Gosselin, J., Bohle, D.S., and Olivier, M. (2009). Synthetic Plasmodium-like hemozoin activates the immune response: a morphology - function study. *PLoS ONE* **4**, e6957.
- Jaramillo, M., Godbout, M., and Olivier, M. (2005). Hemozoin induces macrophage chemokine expression through oxidative stress-dependent and -independent mechanisms. *J. Immunol.* **174**, 475–484.
- Kaisho, T., and Akira, S. (2002). Toll-like receptors as adjuvant receptors. *Biochim. Biophys. Acta* **1589**, 1–13.
- Keller, C.C., Yamo, O., Ouma, C., Ong'echa, J.M., Ounah, D., Hittner, J.B., Vulule, J.M., and Perkins, D.J. (2006). Acquisition of hemozoin by monocytes down-regulates interleukin-12 p40 (IL-12p40) transcripts and circulating IL-12p70 through an IL-10-dependent mechanism: in vivo and in vitro findings in severe malarial anemia. *Infect. Immun.* **74**, 5249–5260.
- Kongkasuriyachai, D., Fujioka, H., and Kumar, N. (2004). Functional analysis of Plasmodium falciparum parasitophorous vacuole membrane protein (Pfs16) during gametocytogenesis and gametogenesis by targeted gene disruption. *Mol. Biochem. Parasitol.* **133**, 275–285.
- Krishnegowda, G., Hajjar, A.M., Zhu, J., Douglass, E.J., Uematsu, S., Akira, S., Woods, A.S., and Gowda, D.C. (2005). Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. *J. Biol. Chem.* **280**, 8606–8616.
- Latz, E., Verma, A., Visintin, A., Gong, M., Sirois, C.M., Klein, D.C., Monks, B.G., McKnight, C.J., Lamphier, M.S., Duprex, W.P., et al. (2007). Ligand-induced conformational changes allosterically activate Toll-like receptor 9. *Nat. Immunol.* **8**, 772–779.
- Lepeniev, B., Cramer, J.P., Burchard, G.D., Wagner, H., Kirschning, C.J., and Jacobs, T. (2008). Induction of experimental cerebral malaria is independent of TLR2/4/9. *Med. Microbiol. Immunol.* **197**, 39–44.
- Martinon, F., Petrilli, V., Mayor, A., Tardivel, A., and Tschopp, J. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature* **440**, 237–241.
- McGee, J.P., Singh, M., Li, X.M., Qiu, H., and O'Hagan, D.T. (1997). The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility. *J. Microencapsul.* **14**, 197–210.
- Muruve, D.A., Petrilli, V., Zaiss, A.K., White, L.R., Clark, S.A., Ross, P.J., Parks, R.J., and Tschopp, J. (2008). The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. *Nature* **452**, 103–107.
- Okech, B., Mujuzi, G., Ogwal, A., Shirai, H., Horii, T., and Egwang, T.G. (2006). High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children. *Am. J. Trop. Med. Hyg.* **74**, 191–197.
- Orengo, J.M., Evans, J.E., Bettiol, E., Leliwa-Sytek, A., Day, K., and Rodriguez, A. (2008). Plasmodium-induced inflammation by uric acid. *PLoS Pathog.* **4**, e1000013.
- Pagola, S., Stephens, P.W., Bohle, D.S., Kosar, A.D., and Madsen, S.K. (2000). The structure of malaria pigment beta-hematin. *Nature* **404**, 307–310.



- Palm, N.W., and Medzhitov, R. (2009). Pattern recognition receptors and control of adaptive immunity. *Immunol. Rev.* 227, 221–233.
- Parroche, P., Lauw, F.N., Goutagny, N., Latz, E., Monks, B.G., Visintin, A., Halmen, K.A., Lamphier, M., Olivier, M., Bartholomeu, D.C., et al. (2007). Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. *Proc. Natl. Acad. Sci. USA* 104, 1919–1924.
- Pichyangkul, S., Yongvanitchit, K., Kum-arb, U., Hemmi, H., Akira, S., Krieg, A.M., Heppner, D.G., Stewart, V.A., Hasegawa, H., Looareesuwan, S., et al. (2004). Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. *J. Immunol.* 172, 4926–4933.
- Pombo, D.J., Lawrence, G., Hirunpetcharat, C., Rzepczyk, C., Bryden, M., Cloonan, N., Anderson, K., Mahakunkijcharoen, Y., Martin, L.B., Wilson, D., et al. (2002). Immunity to malaria after administration of ultra-low doses of red cells infected with *Plasmodium falciparum*. *Lancet* 360, 610–617.
- Pulendran, B., and Ahmed, R. (2006). Translating innate immunity into immunological memory: implications for vaccine development. *Cell* 124, 849–863.
- Reed, S.G., and Scott, P. (1993). T-cell and cytokine responses in leishmaniasis. *Curr. Opin. Immunol.* 5, 524–531.
- Roberts, T.L., Idris, A., Dunn, J.A., Kelly, G.M., Burton, C.M., Hodgson, S., Hardy, L.L., Garceau, V., Sweet, M.J., Ross, I.L., et al. (2009). HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. *Science* 323, 1057–1060.
- Rutz, M., Metzger, J., Gellert, T., Luppa, P., Lipford, G.B., Wagner, H., and Bauer, S. (2004). Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. *Eur. J. Immunol.* 34, 2541–2550.
- Schofield, L., Hewitt, M.C., Evans, K., Siomos, M.A., and Seeberger, P.H. (2002). Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. *Nature* 418, 785–789.
- Seixas, E., Moura Nunes, J.F., Matos, I., and Coutinho, A. (2009). The interaction between DC and *Plasmodium berghei*/chabaudi-infected erythrocytes in mice involves direct cell-to-cell contact, internalization and TLR. *Eur. J. Immunol.* 39, 1850–1863.
- Sounou, G., Viriyakosol, S., Zhu, X.P., Jarra, W., Pinheiro, L., do Rosario, V.E., Thaitong, S., and Brown, K.N. (1993). High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. *Mol. Biochem. Parasitol.* 61, 315–320.
- Stevenson, M.M., and Riley, E.M. (2004). Innate immunity to malaria. *Nat. Rev. Immunol.* 4, 169–180.
- Su, Z., Tam, M.F., Jankovic, D., and Stevenson, M.M. (2003). Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice. *Infect. Immun.* 71, 5178–5187.
- Takehita, F., and Ishii, K.J. (2008). Intracellular DNA sensors in immunity. *Curr. Opin. Immunol.* 20, 383–388.
- Togbe, D., Schofield, L., Grau, G.E., Schnyder, B., Boissay, V., Charron, S., Rose, S., Beutler, B., Quesniaux, V.F., and Ryffel, B. (2007). Murine cerebral malaria development is independent of toll-like receptor signaling. *Am. J. Pathol.* 170, 1640–1648.
- Xiang, S.D., Scholzen, A., Minigo, G., David, C., Apostolopoulos, V., Mottram, P.L., and Plebanski, M. (2006). Pathogen recognition and development of particulate vaccines: does size matter? *Methods* 40, 1–9.

Plasmacytoid Dendritic Cells Delineate Immunogenicity of Influenza Vaccine Subtypes

Shohei Koyama,^{1,2} Taiki Aoshi,³ Takeshi Tanimoto,⁴ Yutaro Kumagai,¹ Kouji Kobiyama,³ Takahiro Tougan,³ Kazuo Sakurai,⁵ Cevayir Coban,¹ Toshihiro Horii,³ Shizuo Akira,^{1*} Ken J. Ishii^{1,3*}

(Published 31 March 2010; Volume 2 Issue 25 25ra24)

A variety of different vaccine types are available for H1N1 influenza A virus infections; however, their immunological mechanisms of action remain unclear. Here, we show that plasmacytoid dendritic cells (pDCs) and type I interferon (IFN)-mediated signaling delineate the immunogenicity of live attenuated virus, inactivated whole-virus (WV), and split virus vaccines. Although Toll-like receptor 7 acted as the adjuvant receptor for the immunogenicity of both live virus and WV vaccines, the requirement for type I IFN production by pDCs for the immunogenicity of the vaccines was restricted to WV. A split vaccine commonly used in humans failed to immunize naïve mice, but a pDC-activating adjuvant could restore immunogenicity. In blood from human adults, however, split vaccine alone could recall memory T cell responses, underscoring the importance of this adjuvant pathway for primary, but not secondary, vaccination.

INTRODUCTION

Vaccination is considered to be the best prophylaxis for influenza virus infection (1). There are three different types of influenza virus vaccines: live attenuated influenza virus (LAIV), formalin-inactivated whole-virus (WV) vaccine, and ether-treated hemagglutinin (HA) antigen-enriched virion-free “split” virus (SV) or “subunit” virus (SU) vaccine (2). Among them, SV and SU are the most commonly used in clinics because there are fewer reactogenicities, although LAIV and WV have been shown to have superior immunogenicity, especially in children (3–5). The immunogenicity and efficacy of these vaccines can be affected by host factors, such as age and immunological status [such as immunodeficiency (6–8)], and viral factors, including the antigenic mismatch between the vaccines and the circulating virus strains (9). However, the exact mechanisms used by the three types of vaccine compositions to achieve immunogenicity and how these mechanisms differ are not fully understood.

It is known that most, if not all, successful vaccines that induce strong protection against pathogens contain adjuvant components that activate the innate immune system via specific receptors, including Toll-like receptors (TLRs), retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), and Nod-like receptors (NLRs) (10–12). These receptors are expressed by antigen-presenting cells, such as dendritic cells (DCs), which mediate the subsequent adaptive immune response by releasing specific cytokines, such as interferons (IFNs) and interleukins (ILs), and activating antigen-specific T and B cells. The nature of the adjuvant and the specific receptors that are activated on DCs can determine the type of immune response that is generated (10–12). Recent studies suggest that TLR7 and a certain NLR that activates the

inflammasome—a collection of components that spur the innate immune system—are involved in controlling adaptive immune responses to influenza A virus infection (13, 14). Our previous work has characterized a key role for TLR signaling in the immune response to inactivated WV vaccination (13); however, no comprehensive study directly compares the role of TLRs, NLRs, and RLRs in either live virus or inactivated WV vaccinations (15). Here, we decipher the mechanism(s) by which the various virus preparations drive development of immunogenicity.

RESULTS

Inactivated WV requires TLR7-mediated, but not RLR- or NLR-mediated, immune activation for its immunogenicity

We first examined whether an inactivated WV preparation of the A/New Caledonia/20/1999 (NC) (H1N1) strain can immunize mice lacking TLR7, IPS-1 (IFN- β promoter stimulator-1; an adaptor protein for RIG-I-mediated type I IFN production), and ASC (apoptotic speck protein; containing a caspase recruitment domain, an adaptor molecule required for NLRP3 inflammasome activation). All three of these genes have been shown to be involved in innate immune recognition of live influenza virus infection (14, 16–19).

We immunized TLR7-deficient or IPS-1-deficient mice intranasally (i.n.) with WV of NC H1N1 twice at a 2-week interval. One week after the second injection, the vaccination-induced, virus-specific B cell and CD4⁺ T cell adaptive immune responses were analyzed. TLR7-deficient mice showed virtually no virus-specific immunoglobulin A (IgA) in bronchoalveolar lavage fluid (BALF), no virus-specific IgG in serum (Fig. 1A), and no IFN- γ production from CD4⁺ T cells specific to a viral nucleoprotein (NP) antigen epitope (NP_{260–283} specific to I-A^b) (Fig. 1B), whereas IPS-1-deficient mice mounted comparable levels of these responses to wild-type mice (Fig. 1, A and B). Consistently, the immunized TLR7-deficient mice were not protected against a lethal challenge with the A/Puerto Rico/8/34 (PR) (H1N1) strain, whereas the immunized IPS-1-deficient mice were protected to a level comparable to vaccinated wild-type mice (Fig. 1C). We

¹Laboratory of Host Defense, WPI Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan. ²Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan. ³Department of Molecular Protozoology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan. ⁴The Research Foundation for Microbial Diseases of Osaka University, Kan-on-ji, Kagawa 768-0061, Japan. ⁵Department of Chemical Processes and Environments, University of Kitakyushu, Kitakyushu, Fukuoka 808-0135, Japan.

*To whom correspondence should be addressed. E-mail: kenishii@biken.osaka-u.ac.jp (K.J.I.); sakira@biken.osaka-u.ac.jp (S.A.)